DKSH

Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field

Retrieved on: 
Friday, December 16, 2022
Osteoporosis, Stada Arzneimittel, PIK, Communication, Partnership, Marketing, Offering, Degenerative disease, Sale, Cancer, DKSH, ISK, USD, Biosimilar, Teva Pharmaceuticals, Respiratory disease, COVID-19, Patient, Security (finance), EU, Bond, Alvogen

REYKJAVIK, Iceland, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced completion of a private placement of approximately US$70 million, at current exchange rates, of subordinated convertible bonds (the “Bonds”), which consists of two tranches, Tranche A and Tranche B, convertible into new fully paid ordinary shares of Alvotech.

Key Points: 
  • Reference is made to the announcement issued earlier today about the completion of a private placement of subordinated convertible bonds.
  • Alvotech intends to use the majority of the net proceeds from the private placement offering to replace a US$50 million unsecured subordinated loan from Alvogen (“Alvogen Facility”) which was announced on November 16, 2022 .
  • In accordance with the Alvogen Facility agreement, associated rights by Alvogen to procure warrants representing up to 4.0% of Alvotech’s ordinary share capital will no longer apply.
  • Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.

Alvotech Completes $59.7 Million Private Placement

Retrieved on: 
Friday, December 16, 2022
Osteoporosis, Stada Arzneimittel, PIK, Communication, Partnership, Marketing, Offering, Degenerative disease, Sale, Cancer, DKSH, ISK, USD, Biosimilar, Teva Pharmaceuticals, Respiratory disease, COVID-19, Patient, Security (finance), EU, Bond, Alvogen

REYKJAVIK, Iceland, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced completion of a private placement of approximately US$59.7 million, at current exchange rates, of subordinated convertible bonds (the “Bonds”), convertible into new fully paid ordinary shares of Alvotech.

Key Points: 
  • REYKJAVIK, Iceland, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced completion of a private placement of approximately US$59.7 million, at current exchange rates, of subordinated convertible bonds (the “Bonds”), convertible into new fully paid ordinary shares of Alvotech.
  • Alvotech intends to use the majority of the net proceeds from the private placement offering to replace a US$50 million unsecured subordinated loan from Alvogen (“Alvogen Facility”) which was announced on November 16, 2022 .
  • Alvotech will issue the Bonds in an aggregate principal amount of approximately US$59.7 million, at today’s exchange rate, in the form of subordinated convertible bonds, with a maturity of 36 months and in two tranches.
  • Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide.

Alvotech Completes $59.7 Million Private Placement

Retrieved on: 
Friday, December 16, 2022
Osteoporosis, Stada Arzneimittel, PIK, Communication, Partnership, Marketing, Offering, Degenerative disease, Sale, Cancer, DKSH, ISK, USD, Biosimilar, Teva Pharmaceuticals, Respiratory disease, COVID-19, Patient, Security (finance), EU, Bond, Alvogen

REYKJAVIK, Iceland, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced completion of a private placement of approximately US$59.7 million, at current exchange rates, of subordinated convertible bonds (the “Bonds”), convertible into new fully paid ordinary shares of Alvotech.

Key Points: 
  • REYKJAVIK, Iceland, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced completion of a private placement of approximately US$59.7 million, at current exchange rates, of subordinated convertible bonds (the “Bonds”), convertible into new fully paid ordinary shares of Alvotech.
  • Alvotech intends to use the majority of the net proceeds from the private placement offering to replace a US$50 million unsecured subordinated loan from Alvogen (“Alvogen Facility”) which was announced on November 16, 2022 .
  • Alvotech will issue the Bonds in an aggregate principal amount of approximately US$59.7 million, at today’s exchange rate, in the form of subordinated convertible bonds, with a maturity of 36 months and in two tranches.
  • Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide.

Alvotech Shares Start Trading on Nasdaq Iceland Main Market

Retrieved on: 
Thursday, December 8, 2022
Osteoporosis, Marketing, Sale, Post Office Passport Seva Kendra, DKSH, Main–Market Historic District, COVID-19, Stada Arzneimittel, Cancer, Nasdaq Iceland, Main, Biosimilar, Nasdaq First North, Degenerative disease, Prospectus, Respiratory disease, Patient, Communication, Teva Pharmaceuticals, Partnership, EU

Robert Wessman Founder and Executive Chairman will ring the Nasdaq Iceland closing bell at 15:30 GMT on December 8, 2022

Key Points: 
  • Robert Wessman Founder and Executive Chairman will ring the Nasdaq Iceland closing bell at 15:30 GMT on December 8, 2022
    Listing on the Main Market can increase visibility, which may allow the company to appear in both domestic and global indexes
    Alvotech became first dual-listed Icelandic company in the U.S. and Iceland after market debut in June, trading under the symbol “ALVO“
    REYKJAVIK, Iceland, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced that trading in its shares will move from the Nasdaq Iceland First North Growth market (“First North”) to the Nasdaq Iceland Main Market (“Main Market”), starting today December 8, 2022.
  • The “ALVO” stock market symbol for Alvotech remains unchanged and trade on the Nasdaq U.S. stock exchange is not affected.  A Main Market listing in Iceland can increase a company’s visibility and, subject to meeting certain conditions, may result in inclusion in Icelandic and international indexes.
  • Alvotech’s shares have been dual listed since June 2022, after being admitted to trading the Nasdaq Stock Market in the U.S. on June 16, 2022 and on First North on June 23, 2022 .
  • On August 12, 2022 , Alvotech’s Board of Directors announced a plan to move the listing from First North to the Main Market and on December 2, 2022 Nasdaq Iceland approved Alvotech’s request to trade its shares on the Main Market.

Alvotech Announces Changes to its Leadership Team

Retrieved on: 
Thursday, December 1, 2022
University, FKA, Alvogen, Cancer, Teva Pharmaceuticals, Patient, Biosimilar, BS, Allergan, Respiratory disease, Partnership, Doctor of Philosophy, Actavis, Pharmacovigilance, DKSH, Teva, Physical pharmacy, CMO, Business administration, Woman, COVID-19, Stada Arzneimittel, Degenerative disease, Executive, Communication, Growth, Marketing, Osteoporosis, R, Management, Fine chemical, EU

Changes to the leadership team are effective January 1, 2023.

Key Points: 
  • Changes to the leadership team are effective January 1, 2023.
  • I am thrilled to welcome Hafrun, who is recognized for her strong leadership in the pharma business, to our team.
  • I am grateful to have been a part of the Alvotech story during an exciting time for the company, Mark Levick said.
  • I had the privilege of working with extremely committed and talented colleagues across the entire team, establishing Alvotech as a commercial company and improving patient access to biologic medicines.

Alvotech Secures Financing Facilities of Approximately $136 Million

Retrieved on: 
Wednesday, November 16, 2022
Marketing, Security (finance), DKSH, Morgan Stanley, Biosimilar, Communication, Osteoporosis, Patient, Degenerative disease, Sculptor Capital Management, Farallon Capital, COVID-19, Growth, Stada Arzneimittel, Landsbankinn, Partnership, Teva Pharmaceuticals, Acquisition, Form 6-K, Respiratory disease, Oaktree Capital Management, Cancer, Alvogen, EU

Alvotech acquires the Reykjavik manufacturing facility, previously utilized under a long-term lease agreement, and secures approximately $16 million, at current exchange rates, in gross loan proceeds through refinancing of secured loan facility

Key Points: 
  • Alvotech acquires the Reykjavik manufacturing facility, previously utilized under a long-term lease agreement, and secures approximately $16 million, at current exchange rates, in gross loan proceeds through refinancing of secured loan facility
    REYKJAVIK, Iceland , Nov. 16, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financing facilities securing gross proceeds of approximately $136 million, at current exchange rates.
  • "These financing facilities are designed to provide flexibility and additional resources for advancing the company's growing biosimilar pipeline, said Joel Morales, Chief Financial Officer of Alvotech.
  • In connection with the acquisition of the manufacturing facility in Reykjavik, Alvotech entered into a secured loan agreement with Landsbankinn hf.
  • to provide for approximately $16 million, at current exchange rates, in gross loan proceeds to Alvotech.

Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference

Retrieved on: 
Thursday, November 10, 2022
DKSH, Psoriasis, Stada Arzneimittel, Partnership, Communication, BLA, Conference, Lightning, Review, Forward-looking statement, Marketing, Biosimilar, Food, SEC, Pharmacokinetics, Cancer, Trial of the century, Patient, Virtual, American College, Private Securities Litigation Reform Act, Osteoporosis, PK, United Kingdom, American College of Rheumatology, Terminology, ACR, Degenerative disease, FDA, GLOBE, Teva Pharmaceuticals, US Foods, NASDAQ, Goal, Safety, Respiratory disease, Pharmaceutical industry, Adalimumab, EU

Alvotech is the only known company that has both developed a high-concentration biosimilar candidate to Humira and completed a switching study to support potential regulatory approval as an interchangeable product.

Key Points: 
  • Alvotech is the only known company that has both developed a high-concentration biosimilar candidate to Humira and completed a switching study to support potential regulatory approval as an interchangeable product.
  • The biosimilarity of AVT02 to Humira has been previously assessed in both a PK study and a confirmatory efficacy and safety study , which supported the assessment of biosimilarity of AVT02.
  • Posters and presentation details will be available to view on the conference platform during the conference.
  • Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide.

DKSH Continues Strengthening its Healthcare Own Brands Business With the Acquisition of two Brands From Eisai

Retrieved on: 
Monday, November 7, 2022
Technology, United Nations Global Compact, Growth, Strategic business unit, DKSH, SIX Swiss Exchange, Vertigo, CHF, OTC, E-commerce, Dizziness, Sustainability, Marketing, Acquisition, Final good, Small Business Saturday, Media relations, Retail, Pharmaceutical industry, Fine chemical, Eisai, Eperisone

With the acquisition, DKSH continues its strategy to expand its Healthcare Own Brands portfolio and to grow in Asia Pacific.

Key Points: 
  • With the acquisition, DKSH continues its strategy to expand its Healthcare Own Brands portfolio and to grow in Asia Pacific.
  • DKSH already markets these products for Eisai in most of the nine Asian markets and with the acquisition now becomes full brand owner.
  • Bijay Singh, Head Business Unit Healthcare at DKSH, commented: This acquisition is another indicator of our commitment to growing our Own Brands portfolio.
  • The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices.

Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance Treatment Merislon in Asia to DKSH

Retrieved on: 
Monday, November 7, 2022
ALA, Technology, United Nations Global Compact, Growth, DKSH, SIX Swiss Exchange, Vertigo, Neurology, Eisai, OTC, E-commerce, Marketing, Eperisone, Final good, Patient, Pharmaceutical industry, Tutoring

Eisai believes that this divestiture agreement will accelerate the pursuit of the best marketing mix in the ALA Region.

Key Points: 
  • Eisai believes that this divestiture agreement will accelerate the pursuit of the best marketing mix in the ALA Region.
  • Under the terms of the agreement, Eisai will receive a contractual up-front payment, and also plan to supply the products.
  • Eisai will retain its manufacturing rights to and continue to distribute the products in countries such as Japan, China and South Korea.
  • *Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines (Myonal only), Singapore, Taiwan (Merislon only), Thailand
    DKSH's purpose is to enrich people's lives.

DKSH Completes the Acquisition of Terra Firma in North America

Retrieved on: 
Thursday, November 3, 2022
Marketing, Final good, Growth, Acquisition, CHF, Technology, Volvo Business Units, Small Business Saturday, E-commerce, Media relations, Firma, DKSH, Food, SIX Swiss Exchange, Terra firma, United Nations Global Compact, Sustainability, Fine chemical

By successfully completing the acquisition of Terra Firma, a leading distributor of specialty chemicals in North America, DKSH expands its platform of the Business Unit Performance Materials in the USA and Canada.

Key Points: 
  • By successfully completing the acquisition of Terra Firma, a leading distributor of specialty chemicals in North America, DKSH expands its platform of the Business Unit Performance Materials in the USA and Canada.
  • Zurich, Switzerland, November 1, 2022 DKSH expands its platform of the Business Unit Performance Materials in the USA and Canada by successfully completing the acquisition of Terra Firma, a leading distributor of specialty chemicals in North America.
  • Stefan Butz, DKSHs CEO, commented: The successful closing of the Terra Firma deal is another step towards building a global distribution platform for specialty chemicals and ingredients.
  • The DKSH Business Unit Performance Materials distributes specialty chemicals and ingredients for food, pharmaceutical, personal care, and various industrial applications.